aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize clinical immunology, Human Immunology Biosciences (HI-Bio) focuses on precision medicine to develop therapies targeting cellular drivers of immune-mediated diseases (IMDs). Their innovative approach aims to provide effective treatments for auto-immune, allergic, and inflammatory conditions, addressing significant unmet medical needs in these areas.
HI-Bio has garnered attention through its pioneering methods and impactful research. The company is supported by notable investors and industry experts who believe in its vision to transform patient care. HI-Bio's achievements in advancing precision medicine have positioned it as a leader in the field, significantly impacting the treatment landscape for IMDs.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Biotech
Technology
Analytics, AI
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was HI-Bio founded?
HI-Bio was founded in 2021.
Where is HI-Bio's headquarters located?
HI-Bio's headquarters is located in San Francisco, CA, US.
When was HI-Bio's last funding round?
HI-Bio's most recent funding round was for $95M (USD) in January 2024.
How many employees does HI-Bio have?
HI-Bio has 48 employees as of Feb 4, 2024.
How much has HI-Bio raised to-date?
As of July 05, 2023, HI-Bio has raised a total of $215M (USD) since Jan 4, 2024.
Add Comparison
Total Raised to Date
$215M
USD
Last Update Jan 4, 2024
Last Deal Details
$95M
USD
Jan 4, 2024
Series B
Total Employees Over Time
48
As of Feb 2024
HI-Bio Address
San Francisco,
California
94115
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts